The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of sapacitabine and seliciclib in patients with advanced solid tumors.
 
Sara M. Tolaney
No Relationships to Disclose
 
John Frederick Hilton
No Relationships to Disclose
 
James M. Cleary
Research Funding - Merck
Travel, Accommodations, Expenses - Roche
 
Leena Gandhi
Honoraria - Merck
Consulting or Advisory Role - Merck; Roche/Genentech
Research Funding - Bristol-Myers Squibb
 
Eunice Lee Kwak
Research Funding - Sanofi (Inst)
Travel, Accommodations, Expenses - Amgen
 
Jeffrey W. Clark
No Relationships to Disclose
 
Andrew Wolanski
No Relationships to Disclose
 
Tracy Demeo Bell
No Relationships to Disclose
 
Scott J. Rodig
Honoraria - Bristol-Myers Squibb; Perkin Elmer
Consulting or Advisory Role - AstraZeneca; Perkin Elmer
Research Funding - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - Patent pending for use of Anti-galectin1 antibodies for diagnostic use.
Travel, Accommodations, Expenses - Roche
 
Judy H. Chiao
Employment - Cyclacel
Stock and Other Ownership Interests - Cyclacel
Patents, Royalties, Other Intellectual Property - Cyclacel
 
David Blake
Employment - Cyclacel
Stock and Other Ownership Interests - Cyclacel
Patents, Royalties, Other Intellectual Property - Cyclacel
 
Geoffrey Shapiro
Consulting or Advisory Role - Chugai Pharma; EMD Serono; G1 Therapeutics; Lilly; Takeda; Tesaro; Vertex
Research Funding - Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Cellceutix (Inst); Covidien (Inst); Cyclacel (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Lilly; Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PTC Therapeutics (Inst); Puma Biotechnology (Inst); Sanofi (Inst); Tensha Therapeutics (Inst); Vertex (Inst)